Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 14/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1608125 | 0.81 | RAPGEF4 (0.44) | RAPGEF4ALDH1A1SMN1; SMN2 | |
| SCHEMBL1608123 | 0.81 | RAPGEF4 (0.44) | RAPGEF4ALDH1A1SMN1; SMN2 | |
| SCHEMBL18966843 | 0.81 | ALDH1A1 (0.34) | ALDH1A1KMT2A | |
| SCHEMBL20584492 | 0.81 | ALDH1A1 (0.34) | ALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL1608097 | 0.79 | RAPGEF4 (0.43) | RAPGEF4ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1608098 | 0.79 | RAPGEF4 (0.43) | RAPGEF4ALDH1A1SMN1; SMN2 | |
| SCHEMBL22753256 | 0.78 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL9501188 | 0.73 | GRIN2D (0.43) | ALDH1A1KMT2A | |
| SCHEMBL9501612 | 0.73 | GRIN2D (0.43) | ALDH1A1KMT2A | |
| SCHEMBL11856863 | 0.69 | RAPGEF4 (0.37) | RAPGEF4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217065-B1 | PREPARATION OF SATURATED IMIDAZOLINIUM SALTS AND RELATED COMPOUNDS | CALIFORNIA INST OF TECHN (US) | 2016-10-12 | — | — | EP | disclosed |
| US-8703965-B2 | Preparation of saturated imidazolinium salts and related compounds | MATERIA, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20110087032-A1 | PREPARATION OF SATURATED IMIDAZOLINIUM SALTS AND RELATED COMPOUNDS | MATERIA, INC. (US) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110087032-A1 | PREPARATION OF SATURATED IMIDAZOLINIUM SALTS AND RELATED COMPOUNDS | NISCH, INF2, DDT | RAPGEF4 1358/4885ALDH1A1 4255/4885GAA 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.